

João E Fonseca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7866585/publications.pdf>

Version: 2024-02-01

183
papers

5,190
citations

109137

35
h-index

110170

64
g-index

191
all docs

191
docs citations

191
times ranked

7619
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Macrophages and Synoviocytes Intracellular Milieu to Augment Anti-inflammatory Drug Potency. <i>Advanced Therapeutics</i> , 2022, 5, .	1.6	0
2	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3
3	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1640-1646.	0.5	12
4	Angiotensin-Converting Enzyme Activity May Predict Disease Severity in Psoriasis. <i>Rheumato</i> , 2022, 2, 15-23.	0.2	1
5	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
6	B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?. <i>Frontiers in Medicine</i> , 2022, 9, 851532.	1.2	6
7	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 32-39.	0.4	3
8	Efficacy of intravenous immunoglobulin in shrinking lung syndrome associated with mixed connective tissue disease: a case report.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
9	Hoarseness as the presentation of immunoglobulin G4-related disease with vocal cord and mediastinal infiltration.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
10	Treatment of relapsing polychondritis: a systematic review.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
11	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
12	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
13	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
14	The Added Value of a Multidisciplinary Clinic for Systemic Autoinflammatory Diseases. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 999-1010.	1.1	1
15	Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 66-70.	0.4	4
16	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 93-102.	0.4	5
17	Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients. <i>Advances in Rheumatology</i> , 2022, 62, .	0.8	1
18	No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e22-e22.	0.5	12

#	ARTICLE	IF	CITATIONS
19	Response to: "The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients" by Favalli <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e76-e76.	0.5	1
20	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. <i>BioDrugs</i> , 2021, 35, 35-45.	2.2	2
21	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
22	A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 695-704.	1.1	8
23	Atherosclerosis and Bone Loss in Humans—Results From Deceased Donors and From Patients Submitted to Carotid Endarterectomy. <i>Frontiers in Medicine</i> , 2021, 8, 672496.	1.2	4
24	Gastric Adenocarcinoma Presenting as a Rheumatoid Factor and Anti-cyclic Citrullinated Protein Antibody-Positive Polyarthritis: A Case Report and Review of Literature. <i>Frontiers in Medicine</i> , 2021, 8, 627004.	1.2	3
25	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1475-1482.	0.5	34
26	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. <i>Frontiers in Immunology</i> , 2021, 12, 672255.	2.2	6
27	Golimumab (anti-TNF monoclonal antibody): where we stand today. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1586-1598.	1.4	12
28	Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review. <i>Frontiers in Medicine</i> , 2021, 8, 689698.	1.2	47
29	Association of body mass index with Juvenile Idiopathic Arthritis disease activity: a Portuguese and Brazilian collaborative analysis. <i>Acta Reumatológica Portuguesa</i> , 2021, 46, 7-14.	0.2	0
30	Ten years of a systemic sclerosis clinic in a tertiary referral centre - insights and future directions. <i>Acta Reumatológica Portuguesa</i> , 2021, 46, 257-265.	0.2	0
31	Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register. <i>Journal of Rheumatology</i> , 2020, 47, 690-700.	1.0	15
32	Efficacy, Safety, and Sample Quality of Ultrasound-Guided Synovial Needle Biopsy in Clinical Practice and Research: A Prospective Observational Study. <i>Arthritis Care and Research</i> , 2020, 72, 1497-1505.	1.5	14
33	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. <i>Arthritis and Rheumatology</i> , 2020, 72, 714-725.	2.9	33
34	Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy. <i>Rheumatology</i> , 2020, 59, .	0.9	1
35	P131—Belimumab in the treatment of 38 portuguese SLE patients: a real-life multicentric study. , 2020, , .		0
36	Elderly-onset rheumatoid arthritis is a unique disease subset associated with poor overall outcomes: Response to the letter by Haroon and Ayamer. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 51, e11-e12.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Giant cell arteritis with normal inflammatory markers: case report and review of the literature. <i>Clinical Rheumatology</i> , 2020, 39, 3115-3125.	1.0	9
38	NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium. <i>Scientific Reports</i> , 2020, 10, 4316.	1.6	14
39	Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. <i>RMD Open</i> , 2020, 6, e001314.	1.8	19
40	GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOLimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 490-498.	0.5	41
41	JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2020, 7, 607725.	1.2	38
42	Arthroscopic Guided Synovial Biopsies. <i>Frontiers in Medicine</i> , 2020, 7, 604582.	1.2	1
43	A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains. <i>Frontiers in Medicine</i> , 2020, 7, 618163.	1.2	14
44	Microbes, helminths, and rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101528.	1.4	7
45	Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 735-743.	1.6	15
46	A COVID-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic. <i>Frontiers in Medicine</i> , 2020, 7, 576162.	1.2	7
47	How did COVID-19 pandemic changed the Portuguese rheumatology?. <i>Acta Reumatológica Portuguesa</i> , 2020, 45, 5-6.	0.2	0
48	Palm-up test and range of motion in flexion and external rotation provide best correlation with disability and perceived pain in patients with shoulder complaints. <i>Acta Reumatológica Portuguesa</i> , 2020, 45, 95-103.	0.2	1
49	Rheumatoid nodule mimicking Morton's neuroma: a rare case report. <i>Acta Reumatológica Portuguesa</i> , 2020, 45, 220-222.	0.2	0
50	Rituximab treatment in a spondyloarthritis patient with low-grade follicular lymphoma: a case report. <i>Acta Reumatológica Portuguesa</i> , 2020, 45, 227-228.	0.2	0
51	Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study. <i>Acta Reumatológica Portuguesa</i> , 2020, 45, 170-176.	0.2	0
52	[Integrated care process for systemic lupus erythematosus: towards quality in healthcare]. <i>Acta Reumatológica Portuguesa</i> , 2020, 45, 295-297.	0.2	0
53	Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy. <i>Acta Reumatológica Portuguesa</i> , 2020, 45, 245-252.	0.2	2
54	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	1.8	28

#	ARTICLE	IF	CITATIONS
55	How to investigate: Pre-clinical rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101438.	1.4	11
56	Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. Scientific Reports, 2019, 9, 14812.	1.6	7
57	Biosimilars in rheumatology. Pharmacological Research, 2019, 149, 104467.	3.1	8
58	Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?. Frontiers in Medicine, 2019, 6, 144.	1.2	18
59	Anti-TNF Drugs for Chronic Uveitis in Adults—A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Medicine, 2019, 6, 104.	1.2	21
60	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis and Rheumatology, 2019, 71, 1616-1625.	2.9	14
61	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	1.8	19
62	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	1.8	91
63	SAT0366—GENDER DIFFERENCES IN PSORIATIC ARTHRITIS — IMPACT ON TUMOR NECROSIS FACTOR INHIBITORS PERSISTENCE AND RESPONSE. , 2019, , .		1
64	FRI0659—REMISSION PERSISTENCE IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS UNDER BIOLOGIC TREATMENT. , 2019, , .		0
65	AB1016—OUTCOME OF TRANSITION OF CARE IN YOUNG ADULTS WITH JUVENILE ONSET CHRONIC RHEUMATIC DISEASES. , 2019, , .		0
66	Cell sources of inflammatory mediators present in bone marrow areas inside the meniscus. PLoS ONE, 2019, 14, e0226986.	1.1	4
67	How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies. Annals of the Rheumatic Diseases, 2019, 78, 25-30.	0.5	14
68	Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000793.	1.8	66
69	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Pharmacogenomics Journal, 2019, 19, 83-96.	0.9	10
70	Treatment of Persistent Cutaneous Atrophy After Corticosteroid Injection With Fat Graft. Reumatologia Clínica, 2019, 15, e122-e124.	0.2	6
71	Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt. Acta Reumatológica Portuguesa, 2019, 44, 57-64.	0.2	5
72	Outcomes of rheumatic patients referred from Portuguese speaking African countries for medical evaluation in Portugal. Acta Reumatológica Portuguesa, 2019, , .	0.2	0

#	ARTICLE	IF	CITATIONS
73	Rheuma SPACE - Standard Practice Aiming Clinical Excellence: description of the methodological approach. <i>Acta Reumatológica Portuguesa</i> , 2019, , .	0.2	0
74	Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center. <i>Acta Reumatológica Portuguesa</i> , 2019, 44, 303-311.	0.2	6
75	Transition in a paediatric rheumatology unit - experience from a tertiary unit. <i>Acta Reumatológica Portuguesa</i> , 2019, 44, 320-321.	0.2	2
76	Loss to follow-up in registries of rheumatic patients treated with biologics: a potential information bias in assessing pharmacovigilance and efficacy outcomes. <i>Acta Reumatológica Portuguesa</i> , 2019, 44, 281-287.	0.2	0
77	Cell sources of inflammatory mediators present in bone marrow areas inside the meniscus. , 2019, 14, e0226986.		0
78	Cell sources of inflammatory mediators present in bone marrow areas inside the meniscus. , 2019, 14, e0226986.		0
79	Cell sources of inflammatory mediators present in bone marrow areas inside the meniscus. , 2019, 14, e0226986.		0
80	Cell sources of inflammatory mediators present in bone marrow areas inside the meniscus. , 2019, 14, e0226986.		0
81	Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. <i>Acta Ophthalmologica</i> , 2018, 96, e665-e675.	0.6	20
82	The Ratio of Blood T Follicular Regulatory Cells to T Follicular Helper Cells Marks Ectopic Lymphoid Structure Formation While Activated Follicular Helper T Cells Indicate Disease Activity in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 774-784.	2.9	94
83	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 1355-1356.	2.9	0
84	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. <i>Arthritis Research and Therapy</i> , 2018, 20, 265.	1.6	29
85	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	1.8	38
86	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , 2018, 4, e000799.	1.8	31
87	Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?. <i>Advances in Rheumatology</i> , 2018, 58, 19.	0.8	39
88	T Follicular Regulatory Cells Are Decreased in Patients With Established Treated Rheumatoid Arthritis With Active Disease: Comment on the Article by Liu et Al. <i>Arthritis and Rheumatology</i> , 2018, 70, 1893-1895.	2.9	14
89	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. <i>Frontiers in Medicine</i> , 2018, 5, 40.	1.2	26
90	Editorial: The Explosion of Biosimilars in Immune Mediated Chronic Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6731-6732.	0.9	0

#	ARTICLE	IF	CITATIONS
91	The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy. <i>Acta Reumatológica Portuguesa</i> , 2018, 43, 80-92.	0.2	2
92	Telerheumatology - breaking barriers to access care in Rheumatology. <i>Acta Reumatológica Portuguesa</i> , 2018, 43, 253-255.	0.2	2
93	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 491-496.	0.5	209
94	Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor- κ B expression in monocytes from patients with early rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000365.	1.8	18
95	Anti-m μ 4/Allerian hormone and ovarian reserve in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2017, 36, 2853-2854.	1.0	16
96	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
97	Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 735-741.	2.9	8
98	Genetic Screening of Mutations Associated with Fabry Disease in a Nationwide Cohort of Juvenile Idiopathic Arthritis Patients. <i>Frontiers in Medicine</i> , 2017, 4, 12.	1.2	6
99	Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	21
100	Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2017, 19, 239.	1.6	38
101	Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors. <i>Frontiers in Medicine</i> , 2017, 4, 5.	1.2	11
102	B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. <i>PLoS ONE</i> , 2017, 12, e0182927.	1.1	72
103	Portuguese Recommendations for the use of biological therapies in patients with rheumatoid arthritis- 2016 update. <i>Acta Reumatológica Portuguesa</i> , 2017, 42(2), 112-126.	0.2	2
104	Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 209-218.	0.2	2
105	Reuma.pt - a case study. <i>Acta Medica Portuguesa</i> , 2016, 29, 83.	0.2	7
106	Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. <i>RMD Open</i> , 2016, 2, e000304.	1.8	47
107	The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 51, 100-109.	2.9	15
108	Differentiating biosimilarity and comparability in biotherapeutics. <i>Clinical Rheumatology</i> , 2016, 35, 2877-2886.	1.0	30

#	ARTICLE	IF	CITATIONS
109	Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?. <i>Current Rheumatology Reports</i> , 2016, 18, 50.	2.1	27
110	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
111	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter "Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016, 43, 208-213.	1.0	30
112	Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. <i>Rheumatology</i> , 2016, 55, 697-703.	0.9	21
113	Biosimilar DMARDs: What Does the Future Hold?. <i>Drugs</i> , 2016, 76, 629-637.	4.9	11
114	Gaps and barriers to tuberculosis screening among anti-tumor necrosis factor prescribers. <i>Acta Reumatológica Portuguesa</i> , 2016, 41, 382-384.	0.2	0
115	Biosimilar monoclonal antibodies: preclinical and clinical development aspects. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 698-705.	0.4	11
116	Brief Report: Tumor Necrosis Factor and Interleukin-6 Differentially Regulate Dkk1 in the Inflamed Arthritic Joint. <i>Arthritis and Rheumatology</i> , 2015, 67, 2071-2075.	2.9	57
117	Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. <i>Arthritis Research and Therapy</i> , 2015, 17, 168.	1.6	11
118	Arthritis Induces Early Bone High Turnover, Structural Degradation and Mechanical Weakness. <i>PLoS ONE</i> , 2015, 10, e0117100.	1.1	13
119	TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	15
120	Genetic Predictors of Poor Prognosis in Portuguese Patients with Juvenile Idiopathic Arthritis: Data from Reuma.pt. <i>Journal of Immunology Research</i> , 2015, 2015, 1-6.	0.9	3
121	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	19
122	Anti-type II collagen antibodies detection and avidity in patients with oligoarticular and polyarticular forms of juvenile idiopathic arthritis. <i>Immunology Letters</i> , 2015, 165, 20-25.	1.1	9
123	Review: Animal Models as a Tool to Dissect Pivotal Pathways Driving Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2813-2827.	2.9	44
124	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. <i>Rheumatology</i> , 2015, 54, 286-291.	0.9	22
125	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. <i>PLoS ONE</i> , 2015, 10, e0122271.	1.1	120
126	Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis. <i>PLoS ONE</i> , 2015, 10, e0144655.	1.1	13

#	ARTICLE	IF	CITATIONS
127	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	1.1	34
128	Expression of the Inherently Autoreactive Idiotope 9G4 on Autoantibodies to Citrullinated Peptides and on Rheumatoid Factors in Patients with Early and Established Rheumatoid Arthritis. PLoS ONE, 2014, 9, e107513.	1.1	10
129	Potent Anti-Inflammatory and Antiproliferative Effects of Gambogic Acid in a Rat Model of Antigen-Induced Arthritis. Mediators of Inflammation, 2014, 2014, 1-7.	1.4	27
130	Pachydermoperiostosis in an African patient caused by a Chinese/Japanese SLCO2A1 mutation—Case report and review of literature. Seminars in Arthritis and Rheumatism, 2014, 43, 566-569.	1.6	20
131	SAPHO Syndrome in an Adolescent: A Clinical Case With Unusual Severe Systemic Impact. Journal of Adolescent Health, 2014, 55, 304-306.	1.2	7
132	Changes in serum RANKL and OPG with sexual development and their associations with bone turnover and bone mineral density in a cohort of girls. Clinical Biochemistry, 2014, 47, 1040-1046.	0.8	5
133	Rheumatoid Arthritis Bone Fragility Is Associated With Upregulation of IL17 and DKK1 Gene Expression. Clinical Reviews in Allergy and Immunology, 2014, 47, 38-45.	2.9	30
134	Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immunosuppression and rituximab. Joint Bone Spine, 2014, 81, 277-278.	0.8	23
135	Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?. Immunologic Research, 2014, 60, 289-310.	1.3	91
136	Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Medicine, 2013, 11, 98.	2.3	50
137	Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?. BMC Medicine, 2013, 11, 17.	2.3	71
138	Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal. BMC Musculoskeletal Disorders, 2013, 14, 279.	0.8	10
139	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics, 2013, 9, e1003394.	1.5	146
140	Protective effect of an ERAP1 haplotype in ankylosing spondylitis: investigating non-MHC genes in HLA-B27-positive individuals. Rheumatology, 2013, 52, 2168-2176.	0.9	34
141	BAFF and TACI Gene Expression Are Increased in Patients with Untreated Very Early Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 1293-1302.	1.0	40
142	Bilateral Evaluation of the Hand and Wrist in Untreated Early Inflammatory Arthritis: A Comparative Study of Ultrasonography and Magnetic Resonance Imaging. Journal of Rheumatology, 2013, 40, 1282-1292.	1.0	44
143	At the moment of occurrence of a fragility hip fracture, men have higher mechanical properties values in comparison with women. BMC Musculoskeletal Disorders, 2013, 14, 295.	0.8	7
144	Gender-Specific Effects of Genetic Variants within Th1 and Th17 Cell-Mediated Immune Response Genes on the Risk of Developing Rheumatoid Arthritis. PLoS ONE, 2013, 8, e72732.	1.1	20

#	ARTICLE	IF	CITATIONS
145	Osteoporosis: from bone biology to individual treatment decision. <i>Acta Medica Portuguesa</i> , 2013, 26, 445-55.	0.2	8
146	Bilateral MR Imaging of the Hand and Wrist in Early and Very Early Inflammatory Arthritis: Tenosynovitis Is Associated with Progression to Rheumatoid Arthritis. <i>Radiology</i> , 2012, 264, 823-833.	3.6	67
147	9G4 expression on autoantibodies to citrullinated peptides in patients with early inflammatory arthritis and established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A24.3-A25.	0.5	2
148	Bilateral 3.0-Tesla MRI of the hand and wrist in early and very early inflammatory arthritis: tenosynovitis is associated with progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A20.3-A21.	0.5	0
149	Effective treatment of rat adjuvant-induced arthritis by celastrol. <i>Autoimmunity Reviews</i> , 2012, 11, 856-862.	2.5	112
150	<i>ANKH</i> and Susceptibility to and Severity of Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2012, 39, 131-134.	1.0	8
151	Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, 2020-2026.	0.9	78
152	Low osteocalcin/collagen type I bone gene expression ratio is associated with hip fragility fractures. <i>Bone</i> , 2012, 51, 981-989.	1.4	23
153	To B or Not to B the Conductor of Rheumatoid Arthritis Orchestra. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 281-291.	2.9	42
154	Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patients. <i>Journal of Bone and Mineral Metabolism</i> , 2012, 30, 692-699.	1.3	9
155	Early Vascular Alterations in SLE and RA Patients—A Step towards Understanding the Associated Cardiovascular Risk. <i>PLoS ONE</i> , 2012, 7, e44668.	1.1	45
156	TNF promoter -308 G>A and LTA 252 A>G polymorphisms in Portuguese patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2012, 32, 2239-2244.	1.5	18
157	Dynamic contrast-enhanced 3-T magnetic resonance imaging: a method for quantifying disease activity in early polyarthritis. <i>Skeletal Radiology</i> , 2012, 41, 51-59.	1.2	17
158	Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts. <i>Clinical Rheumatology</i> , 2012, 31, 447-454.	1.0	10
159	Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review. <i>Clinical Rheumatology</i> , 2012, 31, 385-389.	1.0	14
160	Soluble receptor activator of nuclear factor κ B ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. <i>Arthritis Research and Therapy</i> , 2011, 13, R175.	1.6	19
161	Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects. <i>Arthritis Research and Therapy</i> , 2011, 13, R57.	1.6	70
162	Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. <i>Atherosclerosis</i> , 2011, 219, 821-826.	0.4	40

#	ARTICLE	IF	CITATIONS
163	Upregulation of Inflammatory Genes and Downregulation of Sclerostin Gene Expression Are Key Elements in the Early Phase of Fragility Fracture Healing. PLoS ONE, 2011, 6, e16947.	1.1	39
164	Rheumatoid arthritis: What is refractory disease and how to manage it?. Autoimmunity Reviews, 2011, 10, 707-713.	2.5	27
165	Interleukin-6 promoter polymorphism $\hat{\sim}$ 174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clinical Rheumatology, 2011, 30, 409-413.	1.0	28
166	Lymphotoxin- $\hat{\pm}$ 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in Rheumatoid Arthritis?. Journal of Rheumatology, 2011, 38, 1244-1249.	1.0	16
167	Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology, 2011, 50, 278-282.	0.9	59
168	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Annals of the Rheumatic Diseases, 2011, 70, 1999-2002.	0.5	71
169	Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. Acta Reumatol $\hat{\text{A}}^3$ gica Portuguesa, 2011, 36, 385-8.	0.2	13
170	Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. Clinical Rheumatology, 2010, 29, 629-635.	1.0	13
171	Modulation of IL-17 and Foxp3 Expression in the Prevention of Autoimmune Arthritis in Mice. PLoS ONE, 2010, 5, e10558.	1.1	42
172	Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology, 2010, 49, 1082-1092.	0.9	55
173	Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R196.	1.6	94
174	Chronic arthritis leads to disturbances in the bone collagen network. Arthritis Research and Therapy, 2010, 12, R9.	1.6	26
175	Mechanism of action of strontium ranelate: what are the facts?. Clinical Cases in Mineral and Bone Metabolism, 2010, 7, 17-8.	1.0	17
176	Tumor Necrosis Factor- $\hat{\pm}$ $\hat{\sim}$ 308 Genotypes Influence Inflammatory Activity and TNF- $\hat{\pm}$ Serum Concentrations in Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 837-842.	1.0	23
177	Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1 $\hat{\text{A}}$ year. Clinical Rheumatology, 2009, 28, 1213-1216.	1.0	10
178	Rituximab Use in Pediatric Autoimmune Diseases. Annals of the New York Academy of Sciences, 2009, 1173, 712-720.	1.8	10
179	Ankylosing Spondylitis Susceptibility and Severity $\hat{\text{A}}$ Contribution of TNF Gene Promoter Polymorphisms at Positions $\hat{\text{A}}$ 238 and $\hat{\text{A}}$ 308. Annals of the New York Academy of Sciences, 2009, 1173, 581-588.	1.8	21
180	Assessment of laboratory measurements and $\hat{\sim}$ 308 TNF $\hat{\pm}$ gene promoter polymorphisms in normal bone mineral density. Clinical Rheumatology, 2008, 27, 301-307.	1.0	12

#	ARTICLE	IF	CITATIONS
181	Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter. <i>Arthritis Research and Therapy</i> , 2007, 9, R37.	1.6	32
182	Hoarseness as the presentation of immunoglobulin G4-related disease with vocal cord and mediastinal infiltration. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0
183	Efficacy of intravenous immunoglobulin in shrinking lung syndrome associated with mixed connective tissue disease: a case report. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0